Enanta to end non-biodefense antibiotics program

Enanta Pharmaceuticals said Thursday that it will discontinue development of its antibiotic program for non-biodefense indicators.

The company said it would like to pursue other endeavors in treating and diagnosing the Hepatitis C virus (HCV) and other infectious agents that are more commercially viable. The company's work has included treating Gram-positive bacterial infections, specifically acute bacterial skin and skin structure infections, and it decided to take its research and financial resources in a new direction.

The company is under contract with the National Institute of Allergy and Infectious Disease (NIAID) for its primary antibiotic candidate, EDP-788, which would act as a defense countermeasure to bacteria relating to anthrax, tularemia and bubonic plague. The company's antibiotic program has been funded by NIAID since September 2011.

With the antibiotic program's discontinuation, the company expects that the contract will be terminated for convenience, and the company expects that an agreement to conclude the contract will be made, leaving the company without contractual liability.

The company specializes in the research and development of biotechnology.

Organizations in this Story

National Institute of Allergy and Infectious Diseases (NIAID)

Want to get notified whenever we write about National Institute of Allergy and Infectious Diseases (NIAID) ?
Next time we write about National Institute of Allergy and Infectious Diseases (NIAID), we'll email you a link to the story. You may edit your settings or unsubscribe at any time.